|Bid||76.45 x 100|
|Ask||84.16 x 100|
|Day's Range||77.01 - 80.42|
|52 Week Range||41.76 - 92.98|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Neurocrine Biosciences (NBIX) is a pharmaceutical company with a focus on neurological and endocrine-based diseases and disorders. Its leading product on the market is Ingrezza, a vesicular monoamine transporter 2 (or VMAT2) inhibitor used in the treatment of movement disorders. Ingrezza was approved by the FDA for the treatment of tardive dyskinesia (or TD) in April 2017.
AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug. The agency requested more time to review additional information regarding the results of liver function tests provided by AbbVie in connection with the application for Elagolix in endometriosis-associated pain, the companies said.
AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug. The agency requested more time to review additional information regarding the results of liver function tests provided by AbbVie in connection with the application for Elagolix in endometriosis-associated pain, the companies said. The FDA is now expected to make its decision in the third quarter of 2018, three months later than initially expected.
Who's the world's best hedge fund manager? David Tepper? Stevie Cohen? Try Joe Edelman, a wannabe psychologist with a bead on biotech who has quietly built the best track record of the past two decades.
Teva Pharmaceutical (TEVA) is focused on advancing its specialty assets portfolio, one of its key growth drivers. The company’s specialty products portfolio is made up of Copaxone, Austedo, Fremanezumab, and a number of other assets that are in clinical trials, one of which is Fasinumab.
Neurocrine Biosciences Inc’s (NASDAQ:NBIX): Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The US$7.85B market-cap company announcedRead More...
AbbVie Inc. and Neurocrine Biosciences Inc. shares rose 1.7% and 1.1% respectively in premarket trade Wednesday after the companies announced that their drug met its primary endpoint in a phase 3 trial ...
On Feb. 14, 2018, Neurocrine Biosciences, Inc. (NBIX) announced the company will file a new drug application (NDA) for opicapone in the first half of 2019 following receipt of the meeting minutes from the January 2018 meeting with the FDA. During that meeting, the FDA did not request that Neurocrine conduct an additional Phase 3 study for opicapone prior to filing the NDA. Opicapone is a peripherally-acting and highly selective inhibitor of catechol-o-methyltransferase (COMT) to be used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors in patients with Parkinson’s disease (PD).
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
The San Diego-based company said it had profit of 7 cents per share. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings ...
CEO of Neurocrine Biosciences Inc (NASDAQ:NBIX) Kevin Charles Gorman sold 105,983 shares of NBIX on 02/06/2018 at an average price of $80.25 a share.
Cara Therapeutics’ (CARA) investigational drug candidate, CR845, is being developed for providing pain relief. Intravenous (or IV) CR845 has shown a pain relief and tolerability profile in three Phase 2 clinical trials in patients with acute postoperative pain. Cara Therapeutics has initiated a Phase 3 clinical trial program for IV CR845 for postoperative pain in patients undergoing a range of abdominal surgeries.
Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by targeting peripheral kappa opioid receptors in affected patients. The company is developing a novel class of product candidates that target the body’s peripheral nervous system and certain immune cells. Of the seven analysts covering Cara Therapeutics in January 2018, six analysts gave the stock a “buy” or higher rating, and one recommended “hold.” The stock has a mean rating of 1.9 and a target price of $24.29.
On October 27, 2017, AbbVie (ABBV) announced that the New Drug Application (or NDA) for its investigational drug Elagolix, which is used for managing endometriosis-related pain, had been granted priority review by the FDA. AbbVie has developed Elagolix in collaboration with Neurocrine Biosciences (NBIX). AbbVie expects this oral gonadotropin-releasing hormone (or GnRH) antagonist to be approved by its Prescription Drug User Fee Act (or PDUFA) date in 2Q18.